NFKB1 and non-small cell lung carcinoma: Taken together, these data prove that the ability of lumbrokinase to enhance the chemotherapy sensitivity of NSCLC cells was at least partially achieved by inactivating the NF-κB signaling pathway, thus alleviating the binding of p50/p65 at COX-2 promoter and subsequent COX-2 expression.